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Abstract
Objectives: An aberrant right hepatic artery (aRHA) may pose technical and oncologic challenges during
pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PA) as a result of its proximity to the
head of the pancreas. The aim of this study was to assess the impact of an aRHA on resectability, and
perioperative and oncologic outcomes after PD for PA.
Methods: An 11-year retrospective cohort study was conducted. A total of 289 patients with PA
scheduled for PD with intent for resection were included in the study.
Results: Of 289 patients, 249 underwent PD and 40 were found to have unresectable tumours. Inci-
dences of aRHA in the resectable (14.9%) and unresectable (7.5%) groups were similar (P = 0.2); the main
reasons for aborting PD were not directly related to the presence of an aRHA. In patients who underwent
resection, complications occurred more frequently in the standard PD group (41.5% versus 24.3%; P =
0.04), but there was no difference in rates of positive margin (R1) resection (10.8% versus 16.0%; P = 0.4)
or median overall survival (17 months versus 23 months; P = 0.1) between patients with and without an
aRHA.
Conclusions: The presence of an aRHA in patients with PA does not affect resectability. In patients with
resectable tumours, the presence of an aRHA does not increase morbidity or R1 resection rates and does
not impact on overall survival.
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Introduction
An aberrant right hepatic artery (aRHA) occurs in 15–20% of the
population.1,2 It arises from the superior mesenteric artery (SMA),
courses behind or through the head of the pancreas, and runs
along the posterior aspect of the common bile duct (Fig. 1). The
relevance of the aRHA in pancreaticoduodenectomy (PD) for
cancer is two-fold. Firstly, the artery creates a technical challenge
through its proximity to the structures involved in the PD dissec-
tion and the necessity of preserving it to maintain the blood
supply to the right liver and the bile duct. Secondly, it must be
dissected and preserved during PD in an oncologically sound
manner that achieves negative margin (R0) resection.
Previous studies have investigated outcomes in patients with an
aRHA after PD for various cancers in the head of the pancreas and
found that postoperative outcomes were not compromised by the
presence of an aRHA.3–6 Turrini et al. reported a series of 41
patients with pancreatic adenocarcinoma (PA) and aRHA who
underwent PD, in whom postoperative morbidity and positive
margin rates were not increased.6 However, these studies have
focused on patients submitted to PD and thus the question of
whether the presence of an aRHA affects resectability remains
unanswered. The present study was undertaken to analyse out-
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comes in 289 patients with PA who were initially deemed to be
resectable and were scheduled for PD in order to determine: (i)
the impact of the presence of an aRHA on eventual resectability,
and (ii) the impact of an aRHA on oncologic and postoperative
outcomes after PD at a high-volume hepatopancreatobiliary
(HPB) surgical oncology centre.
Materials and methods
Study design and patient selection
This study was approved by the research ethics board of the Uni-
versity Health Network, University of Toronto, Toronto, Ontario,
Canada (REB no. 11–0073-CE).
The study population included 289 patients with PA who were
initially deemed resectable and were scheduled for PD at the study
institution (University Health Network) from 1 January 2000 to
30 December 2010. The University Health Network is an aca-
demic, university-affiliated, high-volume Canadian HPB centre
with 11 subspecialty trained HPB surgeons. A total of 635 PDs
were performed at this institution during the study time period.
Using retrospective chart review methodology, demographic,
pathologic, postoperative and survival data were analysed.
Of the 289 patients, 249 underwent PD and 40 were found to
have unresectable tumours at the time of laparotomy as a result of
the intraoperative detection of metastatic or locally advanced
disease. To address whether the presence of an aRHA affected
resectability, demographic data, tumour size, National Compre-
hensive Cancer Network (NCCN) stage (resectable versus border-
line versus locally advanced pancreas cancer)7 and the proportions
of patients in the two groups were compared.
To establish whether the presence of an aRHA affects oncologic
and postoperative outcomes in resected patients, the 249 patients
who underwent PD were further divided into those with (aRHA
group) and without (standard PD group) an aRHA. Patient
demographics, tumour characteristics and postoperative out-
comes were compared between these two groups.
The patients with variant upper abdominal arterial anatomy
were identified using the Michels classification system.1 The dif-
ferent types of aRHA are as follows: (i) a replaced RHA that arises
from the SMA, accompanied by a left hepatic artery (LHA) that
arises from the common hepatic artery (CHA); (ii) a replaced
RHA that arises from the SMA, accompanied by a replaced LHA
that arises from the left gastric artery, and (iii) an accessory RHA
that arises from the SMA and accompanies a main RHA that arises
from the CHA. The total replacement of the hepatic artery from
the SMA (coeliomesenteric trunk) and an early take-off of the
RHA from the coeliac artery were also considered to be types of
aRHA (not described by Michels1).
Preoperative management
Preoperative assessment included clinical assessment by an HPB
surgeon, laboratory investigations and imaging by computed
tomography (CT) of the chest and abdomen and/or magnetic
resonance imaging (MRI) of the abdomen.
Surgical technique
A classic PD was performed in all cases. The pancreaticojejunos-
tomy was performed with a retrocolic jejunal limb in end-to-side
fashion with the duct-to-mucosa technique or the invagination
technique according to the surgeon’s preference. This was fol-
lowed by an end-to-side choledochojejunostomy and a standard
gastrojejunostomy. Intraoperative drains were used in 141
(56.6%) patients.
Pathologic analysis
All specimens were processed and interpreted by an experienced
pancreas pathologist. The retroperitoneal margin was defined as
the posterior section of the specimen where the uncinate process
was dissected from the SMA and retroperitoneum (also known as
the SMA margin). The pancreas margin was defined as the cut
surface of the pancreas where the neck of the pancreas was
divided. Pathologic staging was reported according to the seventh
edition of the tumour–node–metastasis (TNM) staging system
supported by the International Union against Cancer (UICC) and
the American Joint Committee on Cancer (AJCC).8
Postoperative complications
Postoperative complications were graded according to the
Clavien–Dindo scale for classifying complications in pancreatic
surgery.9 Pancreatic leak or fistula was defined according to the
definition established by the International Study Group on Pan-
creatic Fistula (ISGPF),10 in which an anastomotic leak is defined
by an amylase-rich output (amylase content three times the upper
limit of normal serum amylase) on or after postoperative day 3.
Pancreatic fistulae were further graded into Grades A (biochemi-
cal fistula with no clinical consequence), B (fistula that requires a
change in clinical management, including the adjustment or inser-
tion of a drain) and C (clinically significant fistula requiring
reoperation), respectively. Delayed gastric emptying (DGE) was
Figure 1 Axial computed tomography of an aberrant right hepatic
artery (aRHA) arising from the superior mesenteric artery (SMA)
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defined as an inability to return to standard diet by the end of the
first week after surgery and the consequent reinsertion of the
nasogastric tube as established by the International Study Group
of Pancreas Surgery (ISGPS).11 Postoperative bleeding was defined
as intra-abdominal or gastrointestinal bleeding in the postopera-
tive period that was significant enough to require blood transfu-
sions and/or reoperation. Complications of Clavien–Dindo Grade
III or higher, any DGE and any postoperative bleeding were con-
sidered to represent major complications.
Statistics
The chi-squared test was used for categorical variables of interest.
Student’s t-test was used for continuous variables. The Kaplan–
Meier product-limit method was used to obtain survival rates over
time. The log-rank test was used to compare overall survival
between patients with and without an aRHA. A P-value of <0.05
was considered to indicate statistical significance.
Results
Classification of an aRHA
As illustrated in Table 1, the classification of aRHA anatomy was
based on that described by Michels.1 Of 289 patients, 40 were
found to have aRHA anatomy; this manifested as a fully replaced
aRHA arising from the SMA in 31 (77.5%) subjects, an accessory
aRHA in three (7.5%) patients, and a replaced aRHA with a con-
comitant replaced LHA in two (5.0%) patients. Total replacement
of the hepatic arterial circulation in which the CHA arose from
the SMA was found in two (5.0%) patients. In another two (5.0%)
patients, the RHA arose directly from the coeliac artery, immedi-
ately distal to its take-off from the aorta, coursed behind the head
of the pancreas and the portal vein and ran along the posterior
lateral aspect of the bile duct. This variant was not described in the
original classification by Michels1, but, because it is similar to a
replaced RHA originating from the SMA, it was included in this
series.
Pancreaticoduodenectomy in patients with an aRHA
As illustrated in Fig. 2, of 289 patients with PA who underwent
exploratory laparotomy with intent for PD, 40 patients underwent
palliative procedures and 249 patients underwent PD (overall
resection rate: 86.2%). Of the 40 patients with an aRHA, 37
underwent PD (resection rate: 92.5%), and of the patients with
standard arterial anatomy, 212 underwent PD (resection rate:
85.1%).
Of the 40 patients submitted to palliative procedures, three
were found to have an aRHA. The presence of an aRHA did not
ultimately determine resectability. In two of these patients, PD was
aborted because of the involvement of the SMA in addition to the
presence of aRHA anatomy. One patient with an aRHA did not
undergo PD as a result of diffuse metastases.
As Table 1 shows, there was no difference in the incidence of an
aRHA between patients who underwent PD and those who did
not (14.9% versus 7.5%; P = 0.2). Although tumour size was
similar in both groups, patients who did not undergo resection
had a higher proportion of borderline resectable tumours accord-
ing to the NCCN preoperative staging system (27.5% versus
10.8%; P = 0.004).
Of 249 patients who underwent PD, 37 patients had aRHA
anatomy (aRHA group) and 212 had standard hepatic arterial
anatomy (standard PD group) (Table 2). Operative variables were
similar between the two groups. Mean standard deviation (SD)
operative times in the aRHA group and the standard PD group
were, respectively, 479  85 min and 439  128 min (P = 0.05).
Median estimated blood loss in the aRHA group and the standard
Table 1 Demographics, preoperative staging and management of patients who did and did not undergo pancreaticoduodenectomy (PD)
Variable Unresected group
(n = 40)
Resected group
(n = 249)
P-value
Age, years, mean  SD 61  10 64  10 0.1
Sex, male : female 27:13 131:118 0.08
Size, cm, mean  SD 3.2  1.1 3.2  1.2 1.0
Aberrant RHA, n (%) 3 (7.5%) 37 (14.9%) 0.2
Types of aberrant RHA, n (%)
Replaced RHA from SMA 3 (100%) 28 (75.7%)
Accessory RHA 0 3 (8.1%)
Replaced RHA and LHA 0 2 (5.4%)
Coeliomesenteric trunk 0 2 (5.4%)
RHA from coeliac artery 0 2 (5.4%)
NCCN staging, n (%)
Resectable 29 (72.5%) 222 (89.2%) 0.004
Borderline 11 (27.5%) 27 (10.8%)
SD, standard deviation; RHA, right hepatic artery; SMA, superior mesenteric artery; LHA, left hepatic artery; NCCN, National Comprehensive Cancer
Network.
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PD group was, respectively, 950 ml and 650 ml (P= 0.5). Incidences
of vascular (portal vein) resections in the aRHA and standard PD
groups were, respectively, 18.9% and 27.8% (P = 0.3). There was a
slightly higher rate of postoperative complications in the standard
PD group (Table 2), but when different types of complication were
compared, no differences emerged between the two groups.
In four patients with aRHA anatomy who underwent PD, the
aRHA was intimately involved or encased with the tumour. Intra-
operative assessment by Doppler ultrasound (US) of intact arte-
rial flow to the right lobe of the liver was performed prior to any
decision on whether an aRHA could be sacrificed. In three
patients, the aRHA was deemed to be an accessory artery (indi-
cated by an intact arterial Doppler signal to the right lobe after
temporary clamping) and was sacrificed to achieve a negative
oncologic margin. In one patient, the aRHA was deemed to be a
replaced RHA and was re-implanted to the stump of the gas-
troduodenal artery (GDA) after the involved segment had been
resected (Fig. 2). All four patients who underwent PD with an
involved aRHA had R0 resection. One additional patient had an
injured aRHA (replaced RHA) that was not involved by the
tumour and was repaired primarily.
Oncologic outcomes
Tumour characteristics were similar between the PD + aRHA and
standard PD groups (Table 3). Mean SD tumour size was 3.4
1.4 cm and 3.1  1.1 cm (P = 0.2) in the aRHA and standard
arterial anatomy groups, respectively. The TNM stage was similar
in both groups. The rate of lymphovascular invasion was signifi-
cantly higher in the standard PD group (65.6% versus 48.7%; P =
0.009). Rates of positive margin (R1) resection were similar in the
PD + aRHA and standard PD groups (10.8% versus 16.0%; P =
0.4). When positive margins were analysed by location, the most
common site was found to be the retroperitoneal margin (SMA
margin).
Although the rate of lymphovascular invasion was higher in the
standard PD group, this did not appear to have an impact on
longterm survival, which was similar in both groups of resected
patients (Fig. 3). Median survival in patients with an aRHA was 17
months, whereas median survival in patients with standard
hepatic arterial anatomy was 23 months (P = 0.1). Rates of 1-, 2-
and 5-year overall survival in patients in the aRHA and standard
arterial anatomy groups were 68%, 36% and 11%, and 70%, 47%
and 20%, respectively.
Univariate and multivariate analyses of the variables found that
size, grade, lymph node involvement, lymphovascular invasion
and positive margin resection were associated with survival
(Tables 4 and 5).
Discussion
The findings of this study show that the presence of an aRHA does
not significantly affect resectability in patients undergoing PD for
PA. When an aRHA was present, the reason for unresectability did
not usually reflect the isolated involvement of the aRHA, but,
rather, the presence of metastases or locally advanced disease
involving major arterial structures (i.e. the SMA). In addition, the
Pancreatic adenocarcinoma scheduled for PD
(n = 289)
Palliative procedures (unresected)
(n = 40)
aRHA
(n = 3)
Locally advanced (n = 2)
Metastases (n = 1)
Accessory RHA sacrificed (n = 3)
Re-implanted (n = 1)
Injured and repaired (n = 1)
aRHA
(n = 37)
Standard
(n = 37)
Standard
(n = 212)
Pancreaticoduodenectomy
(n = 249)
Figure 2 An outline of the management of patients with pancreatic adenocarcinoma with or without an aberrant right hepatic artery (aRHA)
who underwent laparotomy with intent for pancreaticoduodenectomy (PD)
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finding that patients submitted to palliative procedures (unre-
sected patients) did not show an increased incidence of aRHA
further supports the suggestion that an aRHA does not directly
affect resectability. In patients who underwent resection, the pres-
ence of an aRHA did not affect postoperative or oncologic out-
comes, including margin status and overall survival.
In patients in whom the isolated involvement of an aRHA was
identified, R0 resection could be achieved through adherence to
technical and oncologic principles during the resection: an acces-
sory RHA was sacrificed for R0 resection, and a replaced RHA was
resected and re-implanted to achieve an R0 resection.
The importance of preserving a replaced RHA arising from the
SMA during PD has been well described by others. The inadvert-
ent division of the aRHA has been reported to result in ischaemic
breakdown of the bilioenteric anastomosis and subsequent biliary
fistula.12 The common bile duct obtains its blood supply from the
RHA and the retroduodenal artery, a branch of the GDA.13 The
latter is taken during PD and, as a result, inadvertent division of
the RHA renders the common bile duct ischaemic.
Another challenging RHA anatomic anomaly is a replaced RHA
arising from the GDA.14 This variant poses challenges to achieving
an R0 resection because its origin is close to the head of the
pancreas and it can be inadvertently ligated if the GDA is divided
close to its origin on the CHA.
The main surgical principles of PD in a patient with an aRHA
are two-fold: the blood supply to the liver and the common bile
Table 2 Perioperative details of patients who underwent pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma with an aberrant
right hepatic artery (PD + aRHA) and with standard hepatic arterial anatomy (standard PD)
Variable PD + aRHA
(n = 37)
Standard PD
(n = 212)
P-value
Age, years, mean  SD 63  10 64  10 0.3
Sex, male : female 22:15 109:103 0.4
Surgery time, min, mean  SD 479  85 439  128 0.05
Estimated blood loss, ml, median (range) 950 (100–4000) 650 (100–6500) 0.5
Length of stay, days, median (range) 9 (5–39) 10 (5–90) 0.2
Portal vein resection, n (%) 7 (18.9%) 59 (27.8%) 0.3
Type of portal vein resection, n (%) 0.4
Circumferential 5 (13.5%) 34 (16.0%)
Partial 2 (5.4%) 25 (11.8%)
None 30 (81.1%) 153 (72.2%)
Complications (CDC), n (%) 9 (24.3%) 88 (41.5%) 0.04
Grade of complication 0.6
I 0 19 (21.6%)
II 5 (55.6%) 37 (42.0%)
IIIa 3 (33.3%) 18 (20.0%)
IIIb 1 (11.1%) 9 (10.2%)
IV 0 4 (4.5%)
V 0 1 (1.1%)
Pancreatic leak, n (%) 1 (2.7%) 13 (6.1%) 0.7
Type A 0 1 (7.7%)
Type B 1 (100%) 9 (69.2%)
Type C 0 3 (23.1%)
Biliary leak, n (%) 0 1 (0.5%) 1.0
Delayed gastric emptying, n (%) 4 (10.8%) 16 (7.6%) 0.5
Postoperative bleed, n (%) 1 (2.7%) 16 (7.6%) 0.5
Type of bleeding, n (%) 0.06
Intra-abdominal 0 9 (56.3%)
Gastrointestinal 0 7 (43.8%)
Retroperitoneal 1 (100%) 0
Intra-abdominal sepsis, n (%) 4 (10.8%) 26 (12.3%) 1.0
Postoperative mortality, n (%) 0 1 (0.5%) 1.0
SD, standard deviation; CDC, Clavien–Dindo classification.
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duct must be preserved, and the resection must be conducted in
an oncologically sound manner. The present results show that
both principles can be maintained. When resection of the aRHA
was required to achieve an R0 margin, it was sacrificed (resected
and not re-implanted) and deemed to be an accessory RHA. This
action was taken based on the review of preoperative imaging and
the confirmation by Doppler US of an intact arterial blood flow to
the right side of the liver. If the aRHA was thought to be a replaced
RHA, the involved segment of the artery was resected and
re-implanted to maintain the blood supply to the liver and bile
duct. No biliary fistulae were observed in the aRHA group. In fact,
the rate of postoperative complications was slightly higher in the
standard PD group. Although this was not statistically significant,
a trend toward a slightly longer operative time in the aRHA group
was apparent and probably reflected the extra time spent on dis-
secting and constructing the aRHA.
The origin of the aRHA from the SMA occurs at the point at
which the inferior pancreaticoduodenal artery (IPDA) would
arise in PD without an aRHA. Intuitively, if an aRHA is preserved,
it may compromise the oncologic dissection on the SMA, which is
usually facilitated by dividing the IPDA. In the present series, the
presence of an aRHA did not compromise oncologic margins in
that R0 resection rates were similar in patients with and without
an aRHA. Furthermore, there was no difference in survival
between the two groups of patients. The issue of margin may be
more relevant and challenging in patients with an uncinate
tumour that is intimately involved with the aRHA. Four possible
scenarios may arise in this situation: (i) an accessory RHA may be
sacrificed to achieve R0 resection (as in three patients in the
present series); (ii) a replaced RHA may be preserved with a high
risk for R1 resection; (iii) the tumour may be deemed unresectable
because of the concomitant involvement of the SMA (as in two
patients in the present series), and (iv) the involved portion of the
replaced RHA may be resected and reconstructed (as in one
patient in the present series).
Various studies have described the safety of occlusion of aber-
rant hepatic arteries in the setting of hepatic arterial infusion
pump insertions.15–18 It is difficult to apply the lessons learned
from these studies to the present study in which PD was carried
out and bilioenteric anastomoses performed.
To the knowledge of the present authors, this is the first pub-
lished study to specifically address the impact of an aRHA on
Table 3 Oncologic details in patients who underwent pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma with an aberrant right
hepatic artery (PD + aRHA) and standard hepatic arterial anatomy (standard PD)
Variables PD + aRHA
(n = 37)
Standard PD
(n = 212)
P-value
Neoadjuvant therapy, n (%) 1 (2.7%) 13 (6.1%) 0.7
Size, cm, mean  SD 3.4  1.4 3.1  1.1 0.2
Grade (differentiation), n (%) (n = 35) (n = 208) 0.3
Good 10 (28.6%) 39 (18.8%)
Moderate 19 (54.3%) 139 (66.8%)
Poor 6 (17.1%) 30 (14.4%)
Perineural invasion, n (%) 27 (73.0%) 162 (76.4%) 0.09
Lymphovascular invasion, n (%) 18 (48.6%) 139 (65.6%) 0.009
T-stage 1, n (%) 1 (2.7%) 9 (4.2%) 0.9
T-stage 2, n (%) 3 (8.1%) 14 (6.6%)
T-stage 3, n (%) 33 (89.2%) 183 (86.3%)
T-stage 4, n (%) 0 4 (1.9%)
N1, n (%) 27 (73.0%) 159 (75.0%) 0.8
Number of positive LN 3  3 3  3 0.6
Total number of LN 17  7 17  8 0.8
LN ratioa 0.21  0.18 0.24  0.17 0.4
R1 resection, n (%) 4 (10.8%) 34 (16.0%) 0.4
Type of R1 resection, n (%) 1.0
Retroperitoneal 3 (75.0%) 19 (55.9%)
Pancreas 1 (25.0%) 13 (38.2%)
Common bile duct 0 1 (2.9%)
Portal vein 0 1 (2.9%)
aDefined as the ratio between the number of lymph nodes examined and the number of positive lymph nodes.
SD, standard deviation; LN, lymph nodes.
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resectability in PD for pancreatic cancer. The present study is
limited by its failure to capture patients with an aRHA and locally
advanced disease, who were initially deemed to be unresectable.
Therefore, no comment on the impact of an aRHA in locally
advanced PA can be made. In addition, the relatively small
numbers of patients with aRHA anatomy in the unresected and
resected groups may have masked a potentially significant differ-
ence in impact on resectability and survival. A larger series that
includes more patients with an aRHA may help to further eluci-
date the impact of an aRHA on resectability and postoperative
outcome.
In summary, the present findings indicate that the presence of
an aRHA does not appear to affect resectability, or perioperative
and oncologic outcomes in patients with PA who were initially
deemed to have otherwise resectable tumours. If technical and
oncologic principles are observed, PD in patients with an aRHA
can be performed with results similar to those achieved in patients
with standard hepatic arterial anatomy.
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